Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct:85:95-106.
doi: 10.1016/j.semcancer.2021.04.008. Epub 2021 Apr 20.

Notch signaling in cancer: Complexity and challenges on the path to clinical translation

Affiliations
Review

Notch signaling in cancer: Complexity and challenges on the path to clinical translation

Antonio Ferreira et al. Semin Cancer Biol. 2022 Oct.

Abstract

Notch receptors participate in a conserved pathway in which ligands expressed on neighboring cells trigger a series of proteolytic cleavages that allow the intracellular portion of the receptor to travel to the nucleus and form a short-lived transcription complex that turns on target gene expression. The directness and seeming simplicity of this signaling mechanism belies the complexity of the outcomes of Notch signaling in normal cells, which are highly context and dosage dependent. This complexity is reflected in the diverse roles of Notch in cancers of various types, in which Notch may be oncogenic or tumor suppressive and may have a wide spectrum of effects on tumor cells and stromal elements. This review provides an overview of the roles of Notch in cancer and discusses challenges to clinical translation of Notch targeting agents as well as approaches that may overcome these hurdles.

Keywords: Cancer; Notch; Oncogene; Signaling; Tumor suppressor.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Jon C. Aster is a consultant for Ayala Pharmaceuticals and Cellestia, Inc., companies that are developing Notch pathway inhibitors for clinical use. He does not hold an equity position in either company. Antonio Ferreira declares that he has no conflicts of interest.

Publication types

LinkOut - more resources